Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity
Journal of Medicinal Chemistry · 28.03.2024 · 67 (6) · 4977-4997
DOI: 10.1021/acs.jmedchem.4c00102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 11.03.2024. Verfasst von Liu Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 2…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Colonic Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing Municipality, China Postdoctoral Science Foundation, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Programmed death-ligand 1 (PD-L1) has surfaced as a promising therapeutic target for various cancers due to its pivotal role in facilitating tumor immune evasion. Herein, we report a series of novel small-molecule PD-L1 inhibitors exhibiting remarkable inhibitory activity against the PD-1/PD-L1 interaction (X18: IC50 = 1.3 nM) and reinstating the suppressive effect of PD-L1 on T cells (X18: EC50 = 152.8 nM). Crystallographic studies revealed the binding mode of X18 and PD-L1. Through a rational prodrug design approach, we have successfully optimized the oral pharmacokinetic properties of X22, effectively addressing the poor oral pharmacokinetic profile of PD-L1 small-molecule inhibitors. Notably, X22 demonstrated significant antitumor efficacy in murine models of MC38 and CT26 colon cancer through the upregulation of tumor infiltration and cytotoxicity of CD8+ T cells partially. These findings offer promising prospects for the advancement of PD-L1 inhibitors as innovative agents in cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
- Chongqing Innovation Institute of China Pharmaceutical University, Chongqing 401135, China.
- New Drug Screening Center, China Pharmaceutical University, Nanjing 210009, China.
- Jiangsu Flag Chemical Industry Co., Ltd., Nanjing 211500, China.
ORCID-Profile: Xiaoan Wen, Qinglong Xu, Liang Dai, Hongbin Sun, Haoliang Yuan
Förderung
- Natural Science Foundation of Chongqing Municipality
- China Postdoctoral Science Foundation
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
- Jiangsu Funding Program for Excellent Postdoctoral Talen
Zitieren
APA
Liu, L., Zhang, H., Hou, J., Zhang, Y., Wang, L., Wang, S., Yao, Z., Xie, T., Wen, X., Xu, Q., Dai, L., Feng, Z., Zhang, P., Wu, Y., Sun, H., Liu, J., & Yuan, H. (2024). Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity. Journal of Medicinal Chemistry, 67(6), 4977-4997. https://doi.org/10.1021/acs.jmedchem.4c00102
Vancouver
Liu L, Zhang H, Hou J, Zhang Y, Wang L, Wang S, et al. Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity. Journal of Medicinal Chemistry. 2024;67(6):4977-4997. doi:10.1021/acs.jmedchem.4c00102
BibTeX
@article{Liu2024,
author = {Liu, Liu and Zhang, Honghan and Hou, Jie and Zhang, Yuying and Wang, Luosen and Wang, Shijun and Yao, Zhiying and Xie, Tao and Wen, Xiaoan and Xu, Qinglong and Dai, Liang and Feng, Zhiqi and Zhang, Pu and Wu, Yaojun and Sun, Hongbin and Liu, Jun and Yuan, Haoliang},
title = {Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {6},
pages = {4977--4997},
doi = {10.1021/acs.jmedchem.4c00102}
}
EUVIMED